Population Pharmacokinetic and Dynamic Analysis of the Topoisomerase I Inhibitor Lurtotecan in Phase II Studies
Jan H.M. Schellens(Utrecht University), Axel‐R. Hanauske(TUM Klinikum), M. Roelvink, P Dombernowsky(Unknown), Nikolaos Pavlidis(University Hospital of Ioannina), Teresa Gamucci, Hilary Calvert(North Tyneside General Hospital), M. Lehnert(Merck & Co., Inc., Rahway, NJ, USA (United States)), Paul Wissel(University of Pennsylvania), Cristiana Sessa(Institute of Oncology Research), S.B. Kaye(Western Infirmary), K. Selinger(Research Triangle Park Foundation), Jaap Verweij(Deutz (Germany)), Bernhard Heinrich(TUM Klinikum), J. Wanders(Eisai (United Kingdom)), A.T. van Oosterom(Fondazione Vincenzo Pansadoro), H. Cortés-Funes(Centre Hospitalier René-Dubos), Walter J. Loos(Rotterdam University of Applied Sciences), Martin Gore(Imperial College London), Robert Paridaens(Cornell University)
Cited by 10
Related Papers
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k
A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer
|New England Journal of Medicine|2004|1.8k
Cremophor EL
|European Journal of Cancer|2001|1.6k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up
|Annals of Oncology|2015|1.4k